Skip to main content
 

Press Releases

February 15, 2017
 UC’s patent application covering the use of CRISPR/Cas9 genome editing technology with a single-guide RNA format in any non-cellular or cellular setting, including human and other eukaryotic cells, will be released from the interference absent an appeal, and may then be prosecuted to potential issuance Additional legal channels are available to recognize the priority of the University of California/University of Vienna/Charpentier intellectual property covering eukaryotic cells
December 16, 2016

BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA), Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.

October 25, 2016

Bar Harbor, ME and Berkeley, CA – Caribou Biosciences, Inc. and The Jackson Laboratory (JAX) announced an agreement today whereby Caribou has granted JAX non-exclusive worldwide rights to use its CRISPR-Cas9 intellectual property to create genetically engineered mice for research purposes.

September 26, 2016

BERKELEY, CA – September 26, 2016 – Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for genome engineering, announced today that Rachel Haurwitz, Ph.D., President and Chief Executive Officer, has been selected for Fortune magazine’s 2016 “40 Under 40” list, the publication’s annual ranking of the most influential young people in business.  

August 30, 2016

BERKELEY, CA – August 30, 2016 – Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for genome engineering, announced today that Vonnie Estes has joined the Company as Group Leader, Agricultural and Industrial Biotechnology. Ms. Estes brings decades of experience across the agriculture and industrial biotech industries and will lead the Company’s partnership and business development activities in these sectors.

Pages